Medicortex Finland Plc appointing a new advisor
Medicortex is an innovative clinical stage biotechnology company focusing on development of diagnostics and therapy for brain injuries. Company’s short-term focus is to complete development of a rapid urine test, company’s lead product ProbTBITM kit for detection of biomarkers of mild traumatic brain injury, followed by prototype production and clinical evaluation. Professor Hannula will be part of the team to move the company forward to bring its breakthrough products to the clinics to address a significant unmet medical need.
Professor Hannula has a Doctor of Science degree from the Tampere University of Technology and his current position is Vice-Rector for partnerships and strategic engagement at the University of Turku, Finland. He has led the substantial extension of research and education at the University of Turku to technical sciences and headed the establishment of a new faculty of technology. Professor Hannula is an experienced leader and he has extensive experience in different academic leadership positions. Additionally, he serves as a board member or chair for several organizations inside and outside the academia, including private owned companies, public organizations and national defense.
“Medicortex is honored to have one of the most renowned and successful leaders in academia and strategic management to join the Medicortex team in this advisory position. We believe that we have assembled the top multidisciplinary advisory team", says Dr. Adrian Harel, CEO of Medicortex. “The broad potential of our TBI technology pipeline combined with the supplemented outstanding team of experts marks a major step forward in advancing Medicortex to the leading technology company in the field of noninvasive testing of head injury and beyond”, Dr. Harel adds.
“I am happy to join the Advisory Board of Medicortex”, Professor Hannula says. “I’m honored to be part of the team to advise the company at its extremely interesting stage to successfully move forward to get its products on the market. Brain injuries affect a large patient population and we have an outstanding opportunity to make major contributions towards finding an affordable test and reasonable treatment for patients with this condition”, Professor Hannula concludes.
Facts about Professor Mika Hannula
Name: Mika Hannula
Current position: Vice-rector for partnerships and strategic engagement, University of Turku, Finland
- Director (part time), Technology Campus Turku
- President, Tampere University of Technology, Finland
- Professor at both University of Turku, and Tampere University of Technology
Other academic positions
- Chairman, advisory board of National Defense University, Finland
- Adjunct professor, National Defense University
- Adjunct professor, Tampere University
- Doctor of Science (Tech), 1999
- Licentiate of Technology, 1998
- Master of Science (Tech) in Industrial Engineering and Management with distinction, 1993
Military rank: Lieutenant Colonel (in reserve)
Certain statements in this communication are forward-looking statements. They are based on the views of the company’s management, as well as the understanding and assumptions of the company’s management based on the information available at present, and due to this, they may be forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors, which may result in that the company’s actual future results, operations, achievements and performance of the sector may differ significantly from the results, operations, achievements and performance specifically or indirectly indicated in such forward-looking statements. Such risks, uncertainties and other important factors include, among other things, risks related to the implementation of the company’s strategy and availability of financing, general economic and market situation and other risks. Forward-looking statements are not a guarantee of the company’s operational or financial performance in the future.
Adrian HarelCEOTel:+358 400 488 firstname.lastname@example.org
About Medicortex Finland Oyj
Itäinen Pitkäkatu 4 B
Medicortex Finland Oyj is a biotechnology company dedicated to improving the diagnostics and treatment of Traumatic Brain Injury (TBI). Its current focus is on developing biomarker diagnostics to detect brain injury easily. The company has technology to capture biomarkers from urine and saliva and capability to develop an affordable diagnostic tool to detect biomarkers. Company's second goal is to develop new compounds to serve as drug candidates to halt progression of brain injury and reduce the secondary degeneration. Medicortex was founded by an Israeli Neurobiologist Adrian Harel (PhD, MBA) and the company is based in Turku, Finland.
Subscribe to releases from Medicortex Finland Oyj
Subscribe to all the latest releases from Medicortex Finland Oyj by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Medicortex Finland Oyj
Medicortexin kevään 2023 osakeanti päättynyt – yhtiö kiitollinen yleisön mielenkiinnosta30.5.2023 10:45:00 EEST | Tiedote
Medicortex Finland Oyj, tapaturmaisen aivovamman diagnostiikkaa ja hoitoa kehittävä turkulainen bioteknologiayhtiö, on saanut päätökseen osakeantikampanjan toisen kierroksen. Kampanjan aikana, joka sijoittui 2023 vuoden ensimmäiselle puolikkaalle, yritys keräsi yli 110 000 euroa. Saadut varat käytetään uusien hankkeiden aktivoimiseen yhtiön ensisijaisen tuotekehitysprojektin rinnalla.
Medicortex concluding the fundraising round of spring 2023 – company grateful for the public interest30.5.2023 10:45:00 EEST | Press release
Medicortex Finland Plc, a biopharmaceutical company focusing on the development of diagnostics for mild traumatic brain injury (TBI), and drug development for the same indication, announces completion of a second round of the fundraising campaign. In the two funding rounds that took place in the first half of 2023, the company has raised more than 110,000 euros. The funds raised will be used to activate research projects in parallel to company’s main product development program.
Medicortexille uusia osakkaita3.3.2023 13:30:00 EET | Tiedote
Medicortex Finland Oyj, tapaturmaisen aivovamman diagnostiikkaa ja hoitoa kehittävä turkulainen bioteknologiayhtiö, on saanut päätökseen talven osakeantikampanjan. Saadut varat käytetään uusien hankkeiden aktivoimiseen yhtiön ensisijaisen tuotekehitysprojektin rinnalla.
New Shareholders for Medicortex3.3.2023 13:30:00 EET | Press release
Medicortex Finland Plc, a biopharmaceutical company focusing on the development of diagnostics and drug treatment for mild traumatic brain injury (TBI), announces completion of fundraising campaign. The funds raised will be used to activate research projects in parallel to company’s main product development program.
Medicortex Finland Oyj:lle uusi neuvonantaja1.12.2022 09:30:00 EET | Tiedote
Medicortex Finland Oyj, tapaturmaisten aivovammojen diagnostiikkaa ja hoitoa kehittävä turkulainen bioteknologiayhtiö, on nimennyt professori Mika Hannulan (TkT) yhtiön tieteellis-kliiniseen neuvottelukuntaan. Professori Hannula täydentää tutkijoiden ja kliinikoiden tiimiä monipuolisella tieteellisen tutkimuksen johtamisen kokemuksellaan.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom